{
 "as_of": "2026-11-08",
 "cmr": "us-cm-kg/NYSE/MAIA",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# MAIA Biotechnology, Inc. (NYSE: MAIA) — research page\n\nAs of 2026-11-08 · us-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is MAIA Biotechnology, Inc., listed on NYSE under ticker MAIA, with ISIN US5526411021. The LEI is not on the record (no GLEIF record with the exact legal name in jurisdiction US-DE). Security type is Corporate, sector is 2834 Pharmaceutical Preparations, and jurisdiction is United States, Delaware. The segment is not on the record. Listing status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 91 filings across 49 filing days in the window 2025-11-08 to 2026-11-08. By type, the record holds 52 directors' dealings, 14 corporate news, 8 regulatory filings, 7 prospectuses, 5 AGM/EGM filings, 3 results, 1 ad hoc and 1 director change. The median gap between filing days is 4.0 days, against a median of 6.0 days for NYSE and 6.0 days for 2834 Pharmaceutical Preparations. The latest filing is dated 2026-10-07 and is a prospectus, 32 days before the record date of 2026-11-08. Median latency is 4.0 days for NYSE and 4.0 days for the sector, with a median of 64.0 filings for NYSE and 63.0 for the sector.\n\n## Auditor\n\nThe auditor of record is not on the record (no dei:AuditorName tag on the latest annual report cover; foreign private issuers and older filings carry none). Its location is not on the record. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds no listing, delisting or name change lines. The domicile change is not on the record (EDGAR states no dated change of state of incorporation on a filing line). The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The halt flag reads listed, not halted.\n\n## Orderability\n\nThe outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nTwo research houses are named on the issuer's own investor-relations page: Diamond Equity Research and Noble Capital Markets, Inc. The count is 2.\n\n## Open research\n\nNo openly published research notes were found on the record.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe record seals the issuer for the years 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.\n\n## Sources\n\n8 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)\n- https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)\n- https://data.sec.gov/submissions/CIK0001878313.json (identity.jurisdiction)\n- https://mcp.us-cm-kg.ai/events/NYSE/MAIA (the disclosure lines)\n- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)\n- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://ir.maiabiotech.com/company-information/analyst-coverage (coverage)\n- https://mcp.us-cm-kg.ai/record/NYSE/MAIA (the record)\n",
 "market": "US",
 "node": "us-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "live_record_began": "2026-09-12",
   "node_history_from": "2021-01-04",
   "node_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "record_version": 1,
   "sealed": true
  },
  "auditor": {
   "auditor": {
    "market": "US",
    "reason": "no dei:AuditorName tag on the latest annual report cover (foreign private issuers and older filings carry none)",
    "state": "not_on_record"
   },
   "auditor_firm_id": {
    "market": "US",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "US",
    "state": "not_on_record"
   },
   "changes": []
  },
  "cmr": "us-cm-kg/NYSE/MAIA",
  "coverage": {
   "count": 2,
   "houses": [
    {
     "analyst": "Hunter Diamond, CFA",
     "house": "Diamond Equity Research",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.maiabiotech.com/company-information/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Robert LeBoyer",
     "house": "Noble Capital Markets, Inc.",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.maiabiotech.com/company-information/analyst-coverage",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://ir.maiabiotech.com/company-information/analyst-coverage",
     "result": "read: 2 of 4 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-11",
   "since": "not stated on the page read",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 3256,
     "median_cadence_gap_days": 6,
     "median_filings": 64,
     "median_latency_days": 4,
     "name": "NYSE"
    },
    "sector": {
     "issuers": 526,
     "median_cadence_gap_days": 6,
     "median_filings": 63,
     "median_latency_days": 4,
     "name": "2834 Pharmaceutical Preparations"
    }
   },
   "by_type": {
    "ad_hoc": 1,
    "agm_egm": 5,
    "corporate_news": 14,
    "director_change": 1,
    "directors_dealings": 52,
    "prospectus": 7,
    "regulatory_filing": 8,
    "results": 3
   },
   "cadence_median_gap_days": 4,
   "filing_days": 49,
   "filings": 91,
   "latency_days": 32,
   "latest": [
    {
     "category": "424B3",
     "date": "2026-10-07",
     "source": "https://www.sec.gov/Archives/edgar/data/1878313/000149315226046059/form424b3.htm",
     "title": "424B3 — 424B3",
     "type": "prospectus"
    },
    {
     "category": "EFFECT",
     "date": "2026-10-06",
     "source": "https://www.sec.gov/Archives/edgar/data/1878313/999999999526003161/xslEFFECTX01/primary_doc.xml",
     "title": "EFFECT (items ,,)",
     "type": "regulatory_filing"
    },
    {
     "category": "8-K",
     "date": "2026-10-06",
     "source": "https://www.sec.gov/Archives/edgar/data/1878313/000149315226045865/form8-k.htm",
     "title": "8-K — 8-K (items 7.01,9.01)",
     "type": "corporate_news"
    },
    {
     "category": "4",
     "date": "2026-10-02",
     "source": "https://www.sec.gov/Archives/edgar/data/1878313/000187831326000100/xslF345X06/form4.xml",
     "title": "4 — PRIMARY DOCUMENT",
     "type": "directors_dealings"
    },
    {
     "category": "4",
     "date": "2026-10-02",
     "source": "https://www.sec.gov/Archives/edgar/data/1878313/000187831326000099/xslF345X06/form4.xml",
     "title": "4 — PRIMARY DOCUMENT",
     "type": "directors_dealings"
    }
   ],
   "latest_filing_date": "2026-10-07",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.us-cm-kg.ai/events/NYSE/MAIA",
   "window": {
    "from": "2025-11-08",
    "to": "2026-11-08"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NYSE"
   },
   "isin": {
    "read_by": "SEC Fails-to-Deliver data (CUSIP for the symbol) · ISIN = US + CUSIP + ISO 6166 check digit",
    "read_date": "2026-10-01",
    "read_date_basis": "last_seen",
    "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data",
    "state": "sourced",
    "value": "US5526411021"
   },
   "jurisdiction": {
    "read_by": "EDGAR submissions API (issuer header as filed) (stateOfIncorporation)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001878313.json",
    "state": "sourced",
    "value": "United States — Delaware"
   },
   "lei": {
    "market": "US",
    "reason": "no GLEIF record with the exact legal name in jurisdiction US-DE",
    "state": "not_on_record"
   },
   "name": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001878313.json",
    "state": "sourced",
    "value": "MAIA Biotechnology, Inc."
   },
   "sector": {
    "read_by": "EDGAR submissions API (issuer header as filed) (SIC code as assigned by the SEC)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001878313.json",
    "state": "sourced",
    "value": "2834 Pharmaceutical Preparations"
   },
   "security_type": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001878313.json",
    "state": "sourced",
    "value": "Corporate"
   },
   "segment": {
    "market": "US",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "MAIA"
   },
   "website": {
    "market": "US",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": {
    "market": "US",
    "reason": "EDGAR states no dated change of state of incorporation on a filing line",
    "state": "not_on_record"
   },
   "listing": [],
   "name_change": [],
   "segment_move": {
    "market": "US",
    "reason": "the exchanges' tier transfers are not EDGAR filings",
    "state": "not_on_record"
   }
  },
  "market": "US",
  "node": "us-cm-kg",
  "numbers_hash": "sha256:be1c6d7dfc772a24861bc983e9252fc009576f56d5a93fda7a5f48ce8ca1404e",
  "open_research": {
   "read_date": "2026-11-11",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.us-cm-kg.ai/book/aio.json",
    "door": "https://mcp.us-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1",
   "section": "us.aio.v8"
  },
  "record": {
   "as_of": "2026-11-08",
   "url": "https://mcp.us-cm-kg.ai/record/NYSE/MAIA",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:be1c6d7dfc772a24861bc983e9252fc009576f56d5a93fda7a5f48ce8ca1404e",
 "path": "/us/NYSE/MAIA",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is MAIA Biotechnology, Inc., listed on NYSE under ticker MAIA, with ISIN US5526411021. The LEI is not on the record (no GLEIF record with the exact legal name in jurisdiction US-DE). Security type is Corporate, sector is 2834 Pharmaceutical Preparations, and jurisdiction is United States, Delaware. The segment is not on the record. Listing status is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 91 filings across 49 filing days in the window 2025-11-08 to 2026-11-08. By type, the record holds 52 directors' dealings, 14 corporate news, 8 regulatory filings, 7 prospectuses, 5 AGM/EGM filings, 3 results, 1 ad hoc and 1 director change. The median gap between filing days is 4.0 days, against a median of 6.0 days for NYSE and 6.0 days for 2834 Pharmaceutical Preparations. The latest filing is dated 2026-10-07 and is a prospectus, 32 days before the record date of 2026-11-08. Median latency is 4.0 days for NYSE and 4.0 days for the sector, with a median of 64.0 filings for NYSE and 63.0 for the sector.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record is not on the record (no dei:AuditorName tag on the latest annual report cover; foreign private issuers and older filings carry none). Its location is not on the record. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds no listing, delisting or name change lines. The domicile change is not on the record (EDGAR states no dated change of state of incorporation on a filing line). The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The halt flag reads listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "Two research houses are named on the issuer's own investor-relations page: Diamond Equity Research and Noble Capital Markets, Inc. The count is 2.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found on the record.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The record seals the issuer for the years 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "8 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.sec.gov/files/company_tickers_exchange.json"
  },
  {
   "for": "identity.isin",
   "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://data.sec.gov/submissions/CIK0001878313.json"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.us-cm-kg.ai/events/NYSE/MAIA"
  },
  {
   "for": "the halt flag",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.us-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://ir.maiabiotech.com/company-information/analyst-coverage"
  },
  {
   "for": "the record",
   "source": "https://mcp.us-cm-kg.ai/record/NYSE/MAIA"
  }
 ],
 "title": "MAIA Biotechnology, Inc. (MAIA) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}